NasoShield (anthrax intranasal vaccine)
/ Altimmune
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
June 26, 2025
NasoShield Study of Safety and Immunogenicity
(clinicaltrials.gov)
- P1 | N=145 | Completed | Sponsor: Altimmune, Inc. | Unknown status ➔ Completed
Trial completion
May 14, 2021
NasoShield in Healthy Adults to Study Safety and Immunogenicity
(clinicaltrials.gov)
- P1; N=42; Completed; Sponsor: Altimmune, Inc.; Active, not recruiting ➔ Completed
Clinical • Trial completion
January 19, 2021
NasoShield in Healthy Adults to Study Safety and Immunogenicity
(clinicaltrials.gov)
- P1; N=42; Active, not recruiting; Sponsor: Altimmune, Inc.; Trial primary completion date: Nov 2020 ➔ Mar 2021
Clinical • Trial primary completion date
September 30, 2020
NasoShield in Healthy Adults to Study Safety and Immunogenicity
(clinicaltrials.gov)
- P1; N=42; Active, not recruiting; Sponsor: Altimmune, Inc.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
June 18, 2020
NasoShield in Healthy Adults to Study Safety and Immunogenicity
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: Altimmune, Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
June 04, 2020
NasoShield in Healthy Adults to Study Safety and Immunogenicity
(clinicaltrials.gov)
- P1; N=42; Not yet recruiting; Sponsor: Altimmune, Inc.
Clinical • New P1 trial
1 to 6
Of
6
Go to page
1